Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Toripalimab and Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer
NCT07897565Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of gemcitabine, toripalimab, lenvatinib in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
gemcitabinetoripalimablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07897565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897565.